Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000919574-25-003241
Filing Date
2025-05-15
Accepted
2025-05-15 15:35:36
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 9318
2 d11785037_ex99-a.htm EX-99 8036
3 d11785037_ex99-b.htm EX-99 813
  Complete submission text file 0000919574-25-003241.txt   20035
Mailing Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158
Business Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 4154825300
NEKTAR THERAPEUTICS (Subject) CIK: 0000906709 (see all company filings)

EIN.: 943134940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-45385 | Film No.: 25952009
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 500 PARK AVENUE 2ND FLOOR NEW YORK NY 10022
Business Address 500 PARK AVENUE 2ND FLOOR NEW YORK NY 10022 212-848-0519
SAMLYN CAPITAL, LLC (Filed by) CIK: 0001421097 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE
Type: SCHEDULE 13G/A